Mustang Bio, Inc. (MBIO): Price and Financial Metrics
MBIO Price/Volume Stats
| Current price | $0.34 | 52-week high | $8.17 |
| Prev. close | $0.37 | 52-week low | $0.33 |
| Day low | $0.34 | Volume | 138,000 |
| Day high | $0.40 | Avg. volume | 177,270 |
| 50-day MA | $1.02 | Dividend yield | N/A |
| 200-day MA | $2.10 | Market Cap | 3.55M |
MBIO Stock Price Chart Interactive Chart >
Mustang Bio, Inc. (MBIO) Company Bio
Mustang Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products based on the chimeric antigen receptor engineered T cell technology. Its lead programs include MB-101 for the treatment of brain cancer that is in Phase I trials; and MB-102, a therapeutic agent in acute myeloid leukemia, which is in Phase I trials. The company was founded in 2015 and is based in New York, New York. Mustang Bio Inc. is a subsidiary of Fortress Biotech, Inc.
Latest MBIO News From Around the Web
Below are the latest news stories about MUSTANG BIO INC that investors may wish to consider to help them evaluate MBIO as an investment opportunity.
Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual MeetingData showed favorable safety profile, complete response rate and durability in the treatment of patients with relapsed or refractory indolent B-cell Non-Hodgkin Lymphoma 100% of patients with follicular lymphoma achieved a complete response; no occurrence of CRS above grade 1 and no ICANS of any grade Complete responses observed in patients previously treated with CD19-targeted CAR T-cell therapy Outpatient administration found to be feasible WORCESTER, Mass., Dec. 11, 2023 (GLOBE NEWSWIRE) -- M |
Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsWORCESTER, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced financial results and recent corporate highlights for the third quarter that ended September 30, 2023. Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, “I |
Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual MeetingUpdated interim data from Mustang’s multicenter Phase 1/2 clinical trial demonstrate favorable safety and efficacy profile of MB-106 in heavily pre-treated lymphoma patientsWORCESTER, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced that interi |
Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesWORCESTER, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules, for the purchase and sale of 2,588,236 of its shares of com |
Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesWORCESTER, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 2,588,236 of its shares of common stock (or common stock equivalents in li |
MBIO Price Returns
| 1-mo | -69.64% |
| 3-mo | -74.81% |
| 6-mo | -79.76% |
| 1-year | -91.98% |
| 3-year | -99.28% |
| 5-year | -99.64% |
| YTD | -74.81% |
| 2023 | -77.21% |
| 2022 | -76.21% |
| 2021 | -56.14% |
| 2020 | -7.23% |
| 2019 | 38.78% |
Continue Researching MBIO
Want to see what other sources are saying about Mustang Bio Inc's financials and stock price? Try the links below:Mustang Bio Inc (MBIO) Stock Price | Nasdaq
Mustang Bio Inc (MBIO) Stock Quote, History and News - Yahoo Finance
Mustang Bio Inc (MBIO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...